[Galstena therapy of some hepatobiliary diseases].
Galstena was given to 10 patients with chronic cholecystitis, 15 patients with chronic hepatitis and 15 patients with fatty degeneration of the liver for 30 days in a dose 10 drops 3 times a day 30 min before meal. The effect of the drug was assessed in relation to biliary inflammation and motility, inflammation and metabolism in a hepatic cell. It was found that galstena improves motor function of the biliary tract and exocrine function of the liver, reduces activity of mesenchymo-inflammatory syndrome and fatty degeneration of the liver.
Munushkin
O N
ON
D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010758:Phosphorus / Q000627:therapeutic use; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D020011:Protective Agents / Q000627:therapeutic use*; D013431:Sulfates / Q000627:therapeutic use
D004338:Drug Combinations; D028321:Plant Preparations; D020011:Protective Agents; D013431:Sulfates; C012036:sodium sulfate; D010758:Phosphorus